InvestSMART

Noxopharm Limited (ASX: NOX) - Announcements

Current share price for NOX : $0.049 0.006 (10.91%)+

ASX company news and announcements for Noxopharm Limited (NOX) are delayed by 20 minutes from the time of their release between 7.30am and 7.30pm EDT and are in PDF format. All Noxopharm Limited (NOX) ASX announcements deemed to be price sensitive will be highlighted with . If you are looking for ASX announcements for companies other than Noxopharm Limited (NOX), please use our Company Announcements tool to search across all ASX-listed companies.

Latest company announcements for Noxopharm Limited (NOX)

Search all Announcements
Market Cap ($m) Headline Release
date/time+		 Price at
release+		 Current
price+		 Gain/Loss View
$15 Jobkeeper s323DB Notice 20 Oct 2021 4:15PM $0.530 $0.049 fallen by 90.75%
$15 2021 AGM Notice of Meeting and Proxy 15 Oct 2021 8:26AM $0.565 $0.049 fallen by 91.33%
$15 2021 AGM Letter to Shareholders and Proxy 15 Oct 2021 8:19AM $0.565 $0.049 fallen by 91.33%
$15 September 2021 Quarterly Activities Report and Appendix 4C 14 Oct 2021 9:23AM $0.565 $0.049 fallen by 91.33%
$15 Cleansing Notice 29 Sep 2021 6:29PM $0.565 $0.049 fallen by 91.33%
$15 Application for quotation of securities - NOX 29 Sep 2021 6:26PM $0.565 $0.049 fallen by 91.33%
$15 Veyonda Achieves Important U.S. Patent Claims 27 Sep 2021 9:56AM $0.565 $0.049 fallen by 91.33%
$15 Noxopharm 2021 Annual Report 10 Sep 2021 9:47AM $0.510 $0.049 fallen by 90.39%
$15 Noxopharm Updated Corporate Presentation 9 Sep 2021 8:58AM $0.530 $0.049 fallen by 90.75%
$15 Change of Registered Office and Principal Place of Business 30 Aug 2021 1:52PM $0.550 $0.049 fallen by 91.09%
$15 Appendix 4E and Audited Financial Statements 26 Aug 2021 5:38PM $0.570 $0.049 fallen by 91.40%
$15 Appendix 4G and Corporate Governance Statement 26 Aug 2021 5:31PM $0.570 $0.049 fallen by 91.40%
$15 Cleansing Notice 23 Aug 2021 1:42PM $0.605 $0.049 fallen by 91.90%
$15 Application for quotation of securities - NOX 23 Aug 2021 1:39PM $0.595 $0.049 fallen by 91.76%
$15 Pre-clinical Data Supports a Role for Veyonda in COVID-19 23 Aug 2021 10:45AM $0.585 $0.049 fallen by 91.62%
$15 NOXCOVID Program to Expand After Positive Phase 1 Results 23 Aug 2021 9:23AM $0.555 $0.049 fallen by 91.17%
$15 Trading Halt 19 Aug 2021 8:24AM $0.555 $0.049 fallen by 91.17%
$15 Cleansing Notice 13 Aug 2021 2:11PM $0.585 $0.049 fallen by 91.62%
$15 Application for quotation of securities - NOX 13 Aug 2021 2:08PM $0.585 $0.049 fallen by 91.62%
$15 Additional Information on US NCI Collaboration 11 Aug 2021 9:02AM $0.605 $0.049 fallen by 91.90%
$15 NOX and US Govt Peak Cancer Agency Announce Collaboration 9 Aug 2021 8:39AM $0.580 $0.049 fallen by 91.55%
$15 Veyonda Survival Advantage in LuPSMA Therapy Confirmed 5 Aug 2021 9:52AM $0.575 $0.049 fallen by 91.48%
$15 June 2021 Quarterly Activities Report and Appendix 4C 27 Jul 2021 9:10AM $0.625 $0.049 fallen by 92.16%
$15 DARRT-2 Study Receives IND Approval from FDA 1 Jul 2021 8:44AM $0.645 $0.049 fallen by 92.40%
$15 Noxopharm Secures Key European Patent Allowance for Veyonda 29 Jun 2021 12:42PM $0.610 $0.049 fallen by 91.97%

226 - 250 of 804 results

Page 10 of 33

  • + Company announcements and prices are delayed by least 20 minutes. Prices are indicative only.

DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.

Data shown on this website is sourced by Morningstar
© Morningstar. All rights reserved. Neither any Morningstar company nor any of their content providers guarantee the data or content contained herein to be accurate, complete or timely nor will they have any liability for its use or distribution. Any general advice has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892) and/or Morningstar Research Limited, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. You should consider the advice in light of these matters and, if applicable, the relevant Product Disclosure Statement (in respect of Australian products) or Investment Statement (in respect of New Zealand products) before making any decision to invest. No Morningstar-affiliated company or any of their employees is providing you with personalised financial advice. To obtain advice tailored to your particular circumstances, please contact a professional financial adviser. Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). Data and content is provided for personal use only.